Search

A recent study conducted by researchers at the Johns Hopkins Kimmel Cancer Center, in collaboration with other institutions in the United States and Europe, has found that a blood test using artificial intelligence (AI) can help screen women for early signs of ovarian cancer. The test combines AI-powered analyses of DNA fragments and two protein biomarkers, called cancer antigen 125 (CA-125) and human epididymis protein 4 (HE4), to improve screening accuracy and distinguish cancerous tumors from benign growths. Ovarian cancer is the fifth most common cause of cancer deaths among women in the United States, and early detection is crucial for improving survival rates. The researchers plan to further validate the test's utility in larger samples from randomized clinical trials. [Extracted from the article]

A patent has been issued to Regeneron Pharmaceuticals Inc. for the use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation. MUC16 is a glycoprotein that is highly expressed in various cancers and diseases, while CD3 is an antigen expressed on T cells that is required for T cell activation. The patent describes methods for treating cancer by administering an anti-MUC16 antibody or bispecific antigen-binding molecule, along with an anti-4-1BB agonist. The patent also claims that this treatment can decrease tumor volume, increase tumor-free survival time, and elicit a memory response in subjects. The cancers that can be treated include ovarian cancer, breast cancer, pancreatic cancer, and others. [Extracted from the article]

A clinical trial, NCT06566729, has been launched to evaluate the predictive effect of molecular residual disease (MRD) on recurrence events and drug efficacy in high-risk early breast cancer patients. The study will enroll 125 patients and collect perioperative surgical specimens, peripheral blood specimens before and after adjuvant therapy, and follow-up data. The goal is to accurately stratify the risk and guide clinical intervention. The trial is being conducted by Shanghai Jiao Tong University School of Medicine and aims to improve the monitoring and treatment of breast cancer. [Extracted from the article]

A recent study conducted by researchers from Teikyo University School of Medicine explored the efficacy of peritoneal washing cytology (PWC) during interval debulking surgery (IDS) in advanced ovarian cancer. The study retrospectively reviewed the medical records of 25 patients who underwent neoadjuvant chemotherapy and IDS. The results showed that a positive PWC at IDS was not associated with survival in advanced ovarian cancer. The researchers suggest that recent improvements in maintenance therapy may make the combination of CA-125 KELIM and PWC status a more useful prognostic factor in selecting treatment after IDS. Further studies are needed to validate these findings and explore the clinical significance of a positive PWC. [Extracted from the article]

A patent application has been filed for a device, method, and system for detecting ovarian cancer. The invention aims to provide a non-invasive and convenient testing device that can quickly analyze and detect cancers, such as ovarian cancer, using urine samples. The device includes a urine collection vessel with an integrated circuit chip that conducts a microRNA analysis of biomarkers in the collected urine. The testing results can be transmitted wirelessly to a nearby electronic device. The invention addresses the need for early detection of ovarian cancer and provides a more accessible and cost-effective testing option. [Extracted from the article]

A study conducted by researchers from Sao Paulo State University (UNESP) in Guaratingueta, Brazil, explores the potential application of NiFe2O4 magnetic nanoparticles in sensing platforms for the detection of ovarian cancer markers. The nanoparticles were functionalized with cystamine, glutaraldehyde, and PVDF, and then modified with the CA 125 antibody to create an immunosensor. The immunosensor, developed on a printed circuit board, demonstrated excellent stability, reproducibility, specificity, and selectivity. The findings of this research are significant for the development of high-performance point-of-care electrochemical biosensors for detecting the CA 125 antigen, a widely used biomarker for ovarian cancer prognosis. [Extracted from the article]

The article from Hubei Polytechnic University presents new findings on the combined use of carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), and cancer antigen 19-9 (CA19-9) to predict liver metastasis in colorectal cancer patients. Topics discussed include the effectiveness of these tumor markers in early detection, comparative serum levels in patients with and without liver metastases, and the predictive value of CA125.

A study conducted at the Second People's Hospital of Wuhu in Anhui, China, investigated the clinical effects of hepatic artery interventional embolization chemotherapy (TACE) for primary hepatocellular carcinoma (PHC). The study compared the outcomes of patients who received TACE treatment before surgery with those who received only ultrasound-guided microwave ablation treatment. The results showed that the TACE treatment group had higher remission rates, control rates, and levels of the P16 protein, while having lower levels of cancer antigen 125 (CA125), alpha-fetoprotein (AFP), and cancer antigen 19-9 (CA19-9). The study concluded that comprehensive intervention with hepatic artery interventional chemoembolization is more effective in reducing complications and adverse effects in patients with liver cancer. [Extracted from the article]

The document provides information about a clinical trial conducted at the Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University in China. The trial, titled "Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages," aims to evaluate the value of [18F]FDG-PET/CT and CA125 in the early detection of ovarian cancer recurrence, specifically focusing on histological subtypes and tumor stages. The trial is currently recruiting participants and is expected to be completed by May 31, 2026. The primary contact for the trial is Huaiwu Lu, with Dongdong Ye as the backup contact. [Extracted from the article]

A recent study conducted by researchers at Central South University in China aimed to develop an interpretable machine-learning model to predict progression-free survival in patients with epithelial ovarian cancer. The study enrolled 102 patients and used clinical variables and radiomics features to develop the model. The researchers found that CA-125 levels, tumor stage, and Radscore were independent predictors of progression-free survival. The study concluded that the Shapley additive explanation-based interpretation of the prognostic model allows clinicians to better understand the reasoning behind predictions. [Extracted from the article]

Researchers from Sichuan University in China have developed a risk model to predict the prognosis of gallbladder carcinoma (GBC) patients. The model incorporates the prognostic nutritional index and glucose-to-lymphocyte ratio to assign each patient a risk score. The study found that patients in the high-risk group were older, had higher levels of certain serum markers, were more likely to experience postoperative complications, and had more aggressive tumor characteristics. They also had lower overall survival and disease-free survival rates. The risk model can serve as a standalone predictor for prognosis and help optimize treatment approaches for GBC patients. [Extracted from the article]

A recent study conducted by the University of Texas MD Anderson Cancer Center has examined the effectiveness of ovarian cancer screening. The study found that previous screening methods using cancer antigen 125 testing and transvaginal ultrasound did not significantly reduce mortality rates. The researchers used a Bayesian approach to estimate the sojourn time (the period between screen detection and clinical detection) and sensitivity of screening for ovarian cancer. They concluded that annual screening is not effective for all subtypes of ovarian cancer and that the sensitivity of screening for early-stage ovarian cancers is not sufficient for substantial mortality reduction. [Extracted from the article]

A recent study conducted at the Memorial Sloan-Kettering Cancer Center in New York City aimed to develop a pre-operative tool to estimate the risk of blood transfusion during primary debulking surgery for ovarian cancer. The researchers retrospectively reviewed patient data and identified several significant variables that were associated with the odds of receiving a transfusion, including the American Society of Anesthesiologists score, pre-operative levels of cancer antigen 125 (CA125), platelets, obesity, presence of carcinomatosis, bulky upper abdominal disease, pre-operative serum albumin level, and pre-operative hemoglobin level. The researchers developed a scoring system called the BLOODS score, which can help identify patients who would benefit from surgical planning and blood-saving techniques. The study concluded that this model can improve surgical planning and patient outcomes. [Extracted from the article]

A study conducted at Putian University in Fujian, China compared the levels of tumor markers in intraperitoneal drainage fluid between patients who underwent laparoscopic radical gastrectomy and those who underwent open radical gastrectomy for gastric cancer. The study found no significant differences in the levels of carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cancer antigen 199 (CA199), and alpha-fetoprotein (AFP) between the two groups. The study concluded that laparoscopic radical gastrectomy does not increase the risk of intraperitoneal metastasis and there was no significant difference in the 3-year postoperative survival rates between the two groups. [Extracted from the article]

A study conducted by researchers at Chang Gung University in Kaohsiung City, Taiwan, has found that the combination of estrogen receptor/progesterone receptor (ER/PR) expression and cancer antigen 125 (CA 125) level can be used as a biomarker to predict lymph node metastasis (LNM) in patients with endometrioid endometrial cancer (EC). The researchers retrospectively analyzed patients who underwent complete staging surgery and found that an ER/PR H-score below 407 and a CA 125 level of 40 U/mL were independent predictors of LNM. A nomogram was constructed using these variables, which yielded a negative predictive value of 98.3% and a negative likelihood ratio of 0.14. This research provides valuable information for estimating LNM risk and making decisions regarding the need for lymphadenectomy in patients with endometrioid EC. [Extracted from the article]

A recent study conducted in South Korea investigated the prognostic value of the CA-125 elimination rate constant (KELIM) in patients with advanced epithelial ovarian cancer (EOC) who received platinum-based chemotherapy followed by PARP inhibitors. The study found that a favorable KELIM score was associated with improved progression-free survival (PFS) in patients who underwent primary cytoreductive surgery (PCS). Additionally, in patients who underwent interval cytoreductive surgery (ICS), a favorable KELIM score increased the likelihood of achieving complete resection. These findings provide valuable insights into the management and treatment of advanced EOC. [Extracted from the article]

Researchers from Sun Yat-sen University in Guangdong, China have conducted a study on the treatment and prognosis of colorectal cancer with synchronous peritoneal metastases (SPM). The study analyzed the outcomes of patients with colorectal SPM and developed a nomogram to predict their prognosis. The research found that patients who received comprehensive treatment had better prognoses, and the nomogram demonstrated good predictive performance. The study suggests that comprehensive treatment strategies can improve the prognosis of patients with colorectal SPM. [Extracted from the article]

A new report presents fresh data on ovarian cancer, focusing on the need for an objective marker to assess postoperative residual disease. The study evaluated circulating tumor DNA (ctDNA) as a predictive marker for minimum residual disease (MRD) after primary debulking surgery. The researchers used whole genome sequencing to identify structural variants, single nucleotide variants, and indels in tumor tissue, and developed personalized multiplex digital polymerase chain reaction (dPCR) fingerprint assays. The study found that ctDNA levels differed based on postoperative tumor residuals, suggesting that this personalized approach could be used for postoperative MRD evaluation in patients with advanced ovarian cancer. [Extracted from the article]

A patent has been issued for combination vaccine devices and methods of killing cancer cells. The invention involves material-based cancer vaccines combined with immune checkpoint antibodies to enhance T cell activity and anti-tumor immune responses. The device includes an inhibitor of an immune-inhibitory protein, a scaffold composition, a cell recruitment composition, and a bioactive composition. The method aims to treat poorly immunogenic cancers that are resistant to cytotoxic T-lymphocyte (CTL)-mediated lysis or natural killer (NK) cell-mediated killing by administering the inhibitor and the device to the patient. The patent provides detailed information on the components and methods involved in the invention. [Extracted from the article]

A patent application by inventors Gerald Christopher Gooden and Budur Salhia, assigned to the University of Southern California, describes a new method for diagnosing ovarian cancer using a cell-free DNA methylation test. This test measures DNA methylation levels of certain genes to determine the likelihood of having or developing epithelial ovarian cancer. The method aims to improve the accuracy of current diagnostic criteria, allowing for better identification of women who would benefit from surgery. The patent application also mentions the possibility of treating the cancer with radiation therapy, surgery, or therapeutic agents. The method can be applied to samples from whole blood, plasma, serum, or urine. [Extracted from the article]

A study conducted at Zhejiang Cancer Hospital in China examined the effectiveness and safety of combining radiofrequency ablation (RFA) with iodine-125 seeds implantation (RFA-125I) in the treatment of recurrent hepatocellular carcinoma (HCC) after hepatectomy. The study analyzed the clinical data of 210 patients with recurrent HCC, comparing outcomes between the RFA-125I group and the RFA group. The results showed that the RFA-125I group had significantly better overall survival and progression-free survival compared to the RFA group. The study concluded that RFA combined with 125I seeds implantation is an effective and safe treatment for HCC patients with recurrence after hepatectomy. [Extracted from the article]

A new report from the First Affiliated Hospital of Sun Yat-sen University discusses the potential use of the CA-125 elimination rate constant K (KELIM) as a predictor of tumor chemosensitivity in ovarian cancer patients undergoing neoadjuvant chemotherapy (NACT) before interval surgery. The study, conducted in China, analyzed data from 133 patients with high-grade serous ovarian cancer (HGSC) and found that a higher KELIM score was associated with a higher likelihood of complete surgery and better progression-free survival (PFS) and overall survival (OS). The researchers concluded that KELIM could be an important factor in decision-making regarding interval debulking surgery (IDS) attempts and predicting patient survival. [Extracted from the article]

A recent study conducted in New Taipei, Taiwan, explored the use of circulating tumor cells (CTCs) to differentiate between benign ovarian lesions and ovarian cancer before surgery. The study utilized a negative selection strategy followed by flow cytometry to enumerate CTCs in patients with ovarian cancer. The researchers established a cut-off value for CTC number that could distinguish between malignant and benign tumors. The study also found that CTC counts may indicate oncologic outcomes in patients with ovarian cancer who have undergone cancer therapies. [Extracted from the article]

A patent has been issued for bacteriophage-derived nanopore sensors. These sensors have potential applications in cancer diagnosis and high-throughput protein sequencing. The invention involves inserting connector protein channels from bacteriophage DNA packaging motors into copolymeric membranes, creating nanopores that can detect analytes at the single-molecule level. The technology offers advantages over traditional biochemical assays, such as improved sensitivity and faster sample preparation. The patent was assigned to the Ohio State Innovation Foundation, and the inventors are from various institutions in the United States and the United Kingdom. [Extracted from the article]

A study conducted by researchers from Sun Yat-sen University in Guangdong, China, aimed to predict the human epidermal growth factor receptor 2 (HER2) status in patients with gastric cancer (GC) using preoperative contrast-enhanced computed tomography (CECT) imaging features and clinical characteristics. The study found that three CECT imaging features and one serum tumor marker were independently associated with HER2 status in GC: enhancement ratio in the arterial phase, intratumoral necrosis, tumor margin, and cancer antigen 125 (CA125) level. A prediction model derived from these factors showed promise in estimating HER2 status in GC and guiding clinical treatment. This research provides valuable insights for clinicians and researchers in the field of oncology. [Extracted from the article]

A recent report from Brigham and Women's Hospital in Boston, Massachusetts discusses the use of biomarkers for monitoring pleural mesothelioma (PM) after surgery. The study found that soluble mesothelin-related protein (SMRP) levels were associated with certain clinical factors, while cancer antigen 125 (CA-125) levels were not significantly associated with any clinical covariates. SMRP surveillance could be helpful in detecting local recurrences, while CA-125 could aid in recognizing abdominal recurrences. The study provides new insights into the use of biomarkers for monitoring PM after pleurectomy decortication (PD). [Extracted from the article]

Johns Hopkins University has been issued a patent for a method of detecting cancer using cell-free DNA. This method involves identifying genetic alterations in cell-free DNA from a biological sample, such as blood or urine, to detect the presence of circulating tumor DNA. The non-invasive liquid biopsy approach has the potential to detect cancer at an early stage and guide therapeutic interventions. The patent describes the process of extracting cell-free DNA, sequencing it, and identifying sequence alterations to determine the presence of cancer cells. The patent also includes specific genes associated with cancer cell mutations and can be applied to various types of cancer, including lung cancer. [Extracted from the article]

A recent study conducted in Taiyuan, People's Republic of China, examined the relationship between human epididymal protein 4 (HE4) and various factors related to epithelial ovarian cancer (OVCA). The study found that HE4 was highly expressed in OVCA tissues and was associated with the depth of tumor invasion, postoperative recurrence, and metastasis. The study also identified other clinicopathological characteristics that were independent risk factors for prognosis. These findings contribute to a better understanding of OVCA and may have implications for diagnosis and treatment. [Extracted from the article]

A recent study conducted by researchers from Xinjiang Medical University in Urumqi, People's Republic of China, explored the value of serum methylated septin 9 (mSEPT9) and carcinoembryonic antigen (CEA) in the diagnosis, evaluation of treatment effectiveness, and follow-up monitoring of colorectal cancer (CRC). The study analyzed the correlation between serum CEA and mSEPT9 levels with tumor location and size. The results showed that the combined detection of mSEPT9 and CEA can indicate the location and size of colorectal cancer, and the detection of serum mSEPT9 may have clinical significance in evaluating treatment effectiveness and monitoring the progress of colorectal cancer. [Extracted from the article]

A recent study conducted at the National Medical Center in Duarte, California, has found that increased expression of collagen prolyl hydroxylases (P4HA) in ovarian cancer is associated with cancer growth and metastasis. The researchers aimed to assess the role of P4HA in promoting ovarian cancer growth and metastasis by examining the impact of P4HA knockdown on factors such as collagen deposition, cell proliferation, and migration. In vivo studies involving the injection of control and P4HA knockdown cells into mice showed that knockdown of P4HA expression reduced tumor growth and metastases. The study also found that increased P4HA mRNA levels are associated with decreased overall survival in patients with ovarian cancer. These findings suggest that P4HA could serve as a prognostic biomarker and a potential therapeutic target for ovarian cancer. [Extracted from the article]

A recent study conducted by researchers at the Catholic University of Korea has revealed new insights into high-grade serous ovarian carcinoma (HGSOC), a type of ovarian cancer. The study focused on the effects of chemotherapy on tumor cells, stromal cells, and immune cells in HGSOC patients. The researchers found that chemotherapy led to changes in tumor signatures and T-cell profiles, indicating potential therapeutic targets for combating chemotherapy resistance in HGSOC. This study provides valuable information for the development of future treatment strategies for ovarian cancer. [Extracted from the article]

A recent study conducted by researchers at the Sutter Research Institute in San Francisco, California, explored the clinical significance of preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage epithelial ovarian cancer patients. The study enrolled 427 patients with high-risk early-stage ovarian cancer, and it found that 79% of patients had elevated preoperative CA-125 levels. Additionally, elevated pre-chemotherapy CA-125 levels were independently associated with worse recurrence-free survival and overall survival. However, preoperative CA-125 levels were not found to be prognostic. This research provides valuable insights into the role of CA-125 levels in ovarian cancer prognosis. [Extracted from the article]

A recent study conducted at Xuzhou Central Hospital in China examined the impact of neoadjuvant chemotherapy (NAC) on the clinical efficacy and serum tumor marker levels in patients undergoing radical surgery for gastric cancer. The study included 30 patients who received NAC before surgery and 30 patients who underwent routine surgery without NAC. The results showed that the group receiving NAC had a higher proportion of successful tumor removal and lower levels of serum tumor markers compared to the control group. Additionally, the NAC group experienced fewer adverse reactions and improved quality of life. The study concludes that combining NAC with radical surgery for gastric cancer is safe and effective in improving patient outcomes. [Extracted from the article]

A recent study conducted at Taipei Veterans General Hospital in Taiwan explored the relationship between postoperative carbohydrate antigen 125 (CA-125) levels and recurrence in patients with surgical stage I endometrial cancer. The study found that the postoperative CA-125 level was the only independent predictor of recurrence, with a cutoff value of 13.75 U/mL yielding the best sensitivity and specificity for predicting cancer recurrence. Patients with a postoperative CA-125 level >= 13.75 U/mL had a higher recurrence rate and shorter recurrence-free survival (RFS) compared to those with a level <13.75 U/mL. The researchers suggest that obtaining a follow-up CA-125 level within 6 to 12 months after staging surgery may be a promising noninvasive biomarker for predicting recurrence. [Extracted from the article]

A study conducted at Shanghai Jiao Tong University in China has developed dual-antigen-displaying nanovaccines (DADNs) that can simultaneously treat cancer and prevent infectious complications. The DADNs are created by combining immunoadjuvant-loaded nanoparticles with a hybrid coating made from genetically engineered cell membranes expressing tumor and infectious pathogenic antigens. In animal studies, the DADNs were found to stimulate tumor-associated antigen-specific T-cell responses, leading to delayed tumor growth. The nanovaccines also induced protective immunity against tumors and generated pathogenic antigen-specific antibodies. This research offers a promising approach to developing vaccines that can treat cancer and prevent infection simultaneously. [Extracted from the article]

A recent report from the Ottawa Hospital Research Institute highlights the challenges and potential new approaches in treating epithelial ovarian cancer (EOC), which is the most lethal gynecologic cancer. The standard treatment for EOC involves aggressive surgery and platinum-based chemotherapy, but relapse is common and the 5-year mortality rate remains below 45%. The reduced expression of Major Histocompatibility Complexes class I (MHC I) in EOC cases is a major barrier to effective treatment, as it hampers the immune response. The report explores the immunogenicity of ovarian tumors and ongoing immunotherapeutic strategies aimed at stimulating antitumor immunity. [Extracted from the article]

In some variations, the trypsin detection film comprises a substrate and a dye attached to the substrate. In some variations, detecting trypsin in the fluid comprises contacting the trypsin detection film with the fluid and detecting a color change of the trypsin detection film, wherein trypsin is present in the fluid. Keywords: AnX Robotica Corp; Business; Cancer; Enzymes and Coenzymes; Gastroenterology; Genetics; Health and Medicine; Oncology; Pancreas; Pancreas Research; Pancreatic Cancer; Pancreatic Neoplasms; Peptide Hydrolases; Serine Endopeptidases; Trypsin; Ultrasound EN AnX Robotica Corp Business Cancer Enzymes and Coenzymes Gastroenterology Genetics Health and Medicine Oncology Pancreas Pancreas Research Pancreatic Cancer Pancreatic Neoplasms Peptide Hydrolases Serine Endopeptidases Trypsin Ultrasound 1608 1608 1 10/24/23 20231024 NES 231024 2023 OCT 24 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- AnX Robotica Corp (Pleasanton, California, United States) has been issued patent number 11771311, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. In some variations, the trypsin detection film comprises a substrate and a dye attached to the substrate. [Extracted from the article]

Keywords: Adverse Drug Reactions; Aminotransferase; Antibodies; Autoimmunity; Blood Proteins; Brachytherapy; Cancer; Cervical Cancer; Clinical Research; Clinical Trials and Studies; Digestive System Diseases and Conditions; Disease Attributes; Disease Attributes - Disease Progression; Disease Progression; Drugs and Therapies; Enzymes and Coenzymes; Gastroenterology; Genetics; Halogens; Health and Medicine; Hepatitis; Immunoglobulins; Immunology; Immunotherapy; Infectious Diseases and Conditions; Iodine; Liver Diseases and Conditions; Oncology; Proteins; Radiotherapy; Surgery; Therapy; Women's Health EN Adverse Drug Reactions Aminotransferase Antibodies Autoimmunity Blood Proteins Brachytherapy Cancer Cervical Cancer Clinical Research Clinical Trials and Studies Digestive System Diseases and Conditions Disease Attributes Disease Attributes - Disease Progression Disease Progression Drugs and Therapies Enzymes and Coenzymes Gastroenterology Genetics Halogens Health and Medicine Hepatitis Immunoglobulins Immunology Immunotherapy Infectious Diseases and Conditions Iodine Liver Diseases and Conditions Oncology Proteins Radiotherapy Surgery Therapy Women's Health 17 17 1 10/16/23 20231016 NES 231016 2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Staff editors report on the newly launched clinical trial, NCT06062589, which has the following summary description: "The goal of this study is to determine efficacy and safety of AK104 combined with I-125 brachytherapy for recurrent or metastatic cervical cancer. This is an open-label, single-center, observational study of AK104 with Iodine-125 brachytherapy in the treatment of recurrent or metastatic cervical cancer. [Extracted from the article]

Keywords: Cancer; Health and Medicine; Oncology EN Cancer Health and Medicine Oncology 1151 1151 1 10/03/23 20231006 NES 231006 2023 OCT 3 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Fresh data on cancer are presented in a new report. According to news originating from the National Hospital Organization by NewsRx correspondents, research stated, "Elevated serum levels of cancer antigen 125 (CA125) are known to occur in adenomyosis. [Extracted from the article]

The group of nucleic acid molecules of claim 69, wherein the first nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 41, the second nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 25, and the third nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 33. "The bispecific antigen-binding molecules according to this aspect of the present invention comprise a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding domain that specifically binds MUC16. "Certain non-limiting, exemplary anti-CD28/anti-MUC16 bispecific antigen-binding molecules of the invention include a second antigen-binding domain that specifically binds MUC16 comprising HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, having the amino acid sequences selected from the group consisting of: SEQ ID NOs: 4-6-8-12-14-16 and 28-30-32-36-38-40. The group of nucleic acid molecules of claim 56, wherein the first nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 17, the second nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 1, and the third nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 9. [Extracted from the article]

Keywords: Cancer; Endometrial Cancer; Gynecology; Health and Medicine; Oncology; Risk and Prevention; Surgery; Women's Health EN Cancer Endometrial Cancer Gynecology Health and Medicine Oncology Risk and Prevention Surgery Women's Health 880 880 1 09/19/23 20230922 NES 230922 2023 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on endometrial cancer have been presented. Therefore, the aim of the present study was to evaluate whether post-operative carbohydrate antigen 125 (CA-125) levels could be used to predict recurrence and recurrence-free survival (RFS) in patients with surgical stage I endometrial cancer.". [Extracted from the article]

Keywords: Biomarkers; Cancer; Cancer Biomarkers; Carcinoma Biomarkers; Diagnostics and Screening; Emerging Technologies; Energy; Fuel Cell; Health and Medicine; Nanoparticles; Nanotechnology; Oil & Gas; Oncology EN Biomarkers Cancer Cancer Biomarkers Carcinoma Biomarkers Diagnostics and Screening Emerging Technologies Energy Fuel Cell Health and Medicine Nanoparticles Nanotechnology Oil & Gas Oncology 1310 1310 1 09/11/23 20230912 NES 230912 2023 SEP 12 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Fresh data on cancer biomarkers are presented in a new report. Biomarkers, Cancer, Cancer Biomarkers, Carcinoma Biomarkers, Diagnostics and Screening, Emerging Technologies, Energy, Fuel Cell, Health and Medicine, Nanoparticles, Nanotechnology, Oil & Gas, Oncology. [Extracted from the article]